Rigorous evaluation through clinical testing is vital for advancing safe and effective therapies. Clinical trials in regenerative medicine assess how engineered tissues, cell therapies, and gene editing approaches perform in human subjects across a spectrum of conditions. These trials must balance innovation with patient safety, following tightly regulated frameworks to validate therapeutic efficacy and monitor adverse outcomes. From early-phase feasibility studies to large-scale randomized trials, each stage is shaped by complex logistics, including manufacturing standards, delivery methods, and biomarker development. Clinical trials in regenerative medicine also face unique challenges like variability in cell behavior, individualized responses, and long-term monitoring. Despite these hurdles, progress continues steadily, establishing confidence in regenerative approaches through evidence-based evaluation.
Title : The era of artificial intelligence (AI) and its use in regenerative medicine
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Stem cells for human disease modelling and potential for tissue repair
Patrizia Ferretti, UCL Great Ormond Street Institute of Child Health, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : The role of gingival fibroblasts in periodontal diseases and regeneration
Katarzyna Gawron, Medical University of Silesia in Katowice, Poland
Title : Personalized and Precision Medicine (PPM): A unique healthcare model via pathology-related modelling and bi-odesign-inspired translational applications for the next gen-eration of human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation